Envudeucitinib misses the 408-patient lupus trial. Why Alumis still wants a Phase 3 study
Alumis’ 408-patient LUMUS study missed its primary and secondary endpoints in systemic lupus erythematosus, but prespecified interferon-high patients showed stronger responses that the company intends to discuss with regulators.